Publications by authors named "John D Chester"

Claim this Profile
D
Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.
Emily A Bates, James A Davies, Jana Váňová, Davor Nestić, Valerie S Meniel, John D Chester

Mol Ther Oncolytics· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5-A20.
James A Davies, Gareth Marlow, Hanni K Uusi-Kerttula, Gillian Seaton, Luke Piggott, John D Chester

Viruses· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unifying Themes in Urothelial Cancers.
John D Chester

Eur Urol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications.
Sarah L Hulin-Curtis, James A Davies, Davor Nestić, Emily A Bates, Alexander T Baker, John D Chester

Cancer Gene Ther· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ad5-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.
Hanni Uusi-Kerttula, James A Davies, Jill M Thompson, Phonphimon Wongthida, Laura Evgin, John D Chester

Clin Cancer Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.
Sarah L Hulin-Curtis, James A Davies, Rachel Jones, Emma Hudson, Louise Hanna, John D Chester

Oncotarget· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Wales Cancer Research Centre: improving cancer care together.
John D Chester, Jodie R Bond, Elisabeth A Batt

Ecancermedicalscience· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.
Hanni Uusi-Kerttula, James Davies, Lynda Coughlan, Sarah Hulin-Curtis, Rachel Jones, John D Chester

Oncotarget· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalised cancer medicine.
Sarah E Jackson, John D Chester

Int J Cancer· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.
Hanni Uusi-Kerttula, Mateusz Legut, James Davies, Rachel Jones, Emma Hudson, John D Chester

Hum Gene Ther· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Cora N Sternberg, Iwona Skoneczna, J Martijn Kerst, Peter Albers, Sophie D Fossa, John D Chester

Lancet Oncol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Christopher Blick, Peter Hall, Thinn Pwint, Faisal Al-Terkait, Jeremy Crew, John D Chester

Cancer· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?
Jay D Naik, Christopher J Twelves, Peter J Selby, Richard G Vile, John D Chester

Clin Cancer Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours.
Loaie M El-Helw, Jay D Naik, John D Chester, Johnathan K Joffe, Peter J Selby

BJU Int· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic chemotherapy for patients with bladder cancer--current controversies and future directions.
John D Chester, Geoffrey D Hall, Martin Forster, Andrew S Protheroe

Cancer Treat Rev· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
John D Chester, Simon P Joel, Susan L Cheeseman, Geoffrey D Hall, Michael S Braun

J Clin Oncol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis